TransCode completes Phase 1a trial for TTX-MC138 with no dose-limiting toxicities
TransCode Therapeutics announced positive Phase 1a results for its lead candidate TTX-MC138, showing safety, tolerability, and disease stabilization in metastatic cancer patients across all dose cohorts. The company will advance to Phase 2a development targeting ctDNA-positive colorectal cancer patients.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day